Hong et al. (Hong, et al., 2019) found that the vascular endothelial growth factual-C (VEGF-C) was a key target of PTFC in the treatment of NAFLD through network pharmacological analysis. The gene discussed is VEGFC; the disease is metabolic dysfunction-associated steatotic liver disease.